Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Carcinoma, Renal Cell 12Prostatic Neoplasms 4Kidney Neoplasms 4Neoplasms 3Carcinoma, Hepatocellular 3Sarcoma, Ewing 2Osteosarcoma 2Neuroendocrine Tumors 2Neoplasm Metastasis 2Melanoma 2Lung Neoplasms 2Clear-cell metastatic renal cell carcinoma 2Carcinoma, Transitional Cell 2Carcinoma, Non-Small-Cell Lung 2Carcinoma, Medullary 2Carcinoma 2Adrenocortical Carcinoma 2von Hippel-Lindau Disease 1Wilms Tumor 1Urogenital Neoplasms 1Urinary Bladder Neoplasms 1Urethral Neoplasms 1Urachal adenocarcinoma 1Triple Negative Breast Neoplasms 1Thyroid Neoplasms 1Thyroid Cancer, Papillary 1Squamous Cell Carcinoma of Head and Neck 1Small Cell Lung Carcinoma 1Sarcoma, Kaposi 1Sarcoma, Clear Cell 1

Interventions

Gemcitabine 11Magnetic Resonance Spectroscopy 10Specimen Handling 8Cisplatin 7pembrolizumab 6Radiation 5Mitomycin 4Fluorouracil 4Cystoscopy 4enfortumab vedotin 3durvalumab 3dehydroftorafur 3avelumab 3Transurethral Resection of Bladder 3Radiotherapy 3Platinum 3Nivolumab 3Mitozytrex 3Cystectomy 31,2-diaminocyclohexaneplatinum II citrate 3ulixertinib 2tremelimumab 2erdafitinib 2atezolizumab 2Paclitaxel 2Immunoglobulin G 2Docetaxel 2Disulfides 2Carboplatin 2Biopsy 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Urinary Bladder Neoplasms × cabozantinib × 30 days × Clear all
NCT03866382 2026-06-03

Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors

National Cancer Institute (NCI)

Phase 2 Recruiting
314 enrolled
Genitourinary

Urachal adenocarcinoma, Urinary Bladder Neoplasms, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Penile Neoplasms, Prostatic Neoplasms, Urethral Neoplasms, Urogenital Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡